We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

LabMedica

Download Mobile App
Recent News Expo Clinical Chem. Molecular Diagnostics Hematology Immunology Microbiology Pathology Technology Industry Focus

Salivary Glucose Levels Measured by Biochip Sensor

By LabMedica International staff writers
Posted on 18 Jun 2014
Image: The schematic shows glucose molecules sliding along the biochip sensor surface illuminated by different colors. Change in light intensity transmitted through the slits of each plasmonic interferometer can be used to measure the glucose concentration in saliva (Photo courtesy of Domenico Pacifici, PhD).
Image: The schematic shows glucose molecules sliding along the biochip sensor surface illuminated by different colors. Change in light intensity transmitted through the slits of each plasmonic interferometer can be used to measure the glucose concentration in saliva (Photo courtesy of Domenico Pacifici, PhD).
A new biochip sensor has been developed that can selectively measure concentrations of glucose in a complex solution similar to human saliva.

The new chip makes use of a series of specific chemical reactions combined with plasmonic interferometry which is a means of detecting chemical signature of compounds using light. The device is sensitive enough to detect differences in glucose concentrations that amount to just a few thousand molecules in the sampled volume.

Scientists at Brown University (Providence, RI, USA) exploited the synergistic advantage of combining plasmonic interferometry with an enzyme-driven dye assay that yields an optical sensor capable of detecting glucose in saliva with high sensitivity and selectivity. The biochip is made from a 2.54 x 2.54-cm piece of quartz coated with a thin layer of silver. Etched in the silver are thousands of nanoscale interferometers, tiny slits with a groove on each side. The grooves measure 200 nm wide and the slit is 100 nm wide.

When a liquid is deposited on the chip, the light and the surface plasmon waves propagate through that liquid before they interfere with each other. That alters the interference patterns picked up by the detectors, depending on the chemical makeup of the liquid. The scientists added microfluidic channels to the chip to introduce two enzymes that react with glucose in a very specific way. The first enzyme, glucose oxidase, reacts with glucose to form a molecule of hydrogen peroxide. This molecule then reacts with the second enzyme, horseradish peroxidase, to generate a molecule called resorufin, which can absorb and emit red light, thus coloring the solution. The team could then tune the interferometers to look for the red resorufin molecules.

The team tested its combination of dye chemistry and plasmonic interferometry by looking for glucose in artificial saliva, a mixture of water, salts and enzymes that resembles the real human saliva. They found that they could detect resorufin in real time with great accuracy and specificity. They were able to detect changes in glucose concentration of 0.1 μM/L, which is 10 times the sensitivity that can be achieved by interferometers alone. The proposed device is highly sensitive and highly specific for glucose sensing in picoliter volumes, across the physiological range of glucose concentrations found in human saliva, which is 20 μM–240 μM.

Domenico Pacifici, PhD, an assistant professor of engineering, and who led the study, said, “We have demonstrated the sensitivity needed to measure glucose concentrations typical in saliva, which are typically 100 times lower than in blood. Now we are able to do this with extremely high specificity, which means that we can differentiate glucose from the background components of saliva.” The study was published in the June 2014 edition of the journal Nanophotonics.

Related Links:

Brown University

Platinum Member
Automated Coagulation Analyzer
Hemolumi H6
New
Gold Member
Platelet Function Analyzer
PL-12
Prefilled Tubes
Prefilled 5.0ml Tubes
Platinum Member
Integrated Biochemical & Immunological System
Biolumi CX Solution X10+C10

Channels

Molecular Diagnostics

view channel
Image: The researchers Manel Pérez Pons y Carlos Rodriguez Muñoz at the IRBLleida laboratory (Photo courtesy of IRBLleida)

New Blood RNA Markers Help Advance Precision Medicine for Respiratory Patients

Risk stratification in hospitalized respiratory disease, particularly among older adults with COVID-19, remains challenging despite rich clinical datasets. Blood-based non-coding RNA biomarkers are promising,... Read more

Microbiology

view channel
Image: The “broth” used to monitor red blood cell depletion in whole blood spiked with one colony-forming-unit of E. coli bacteria, each incubated at different orbital shaking speeds—left to right: 0 RPM, 65 RPM, 120 RPM and 200 RPM—after four hours of incubation. This culturing raises a bacteria-rich, plasma-like layer of bacteria to the top of the vials, while clusters of stuck blood cells known as a Rouleaux formation sink to the bottom. (Image Credit: Pak Kin Wong)

New Diagnostic Workflow Identifies Bloodstream Pathogens and Antibiotic Response in Hours

Sepsis is a life-threatening complication of infection that affects more than 1.5 million patients annually in the United States and contributes to roughly one in three in-hospital deaths.... Read more

Pathology

view channel
Image: Researchers evaluated AI models that quantify tumor-infiltrating lymphocytes (TIL) on routine breast tissue slides, where higher TIL levels reflect stronger antitumor response and improved breast cancer outcomes (Image Credit: Shutterstock)

AI Matches Pathologists in Predicting Breast Cancer Prognosis from Immune Cells

Breast cancer is the most common cancer in Australian women, with more than 20,000 cases each year. Prognosis can be informed by counting tumor-infiltrating lymphocytes (TILs) on routine pathology slides,... Read more

Industry

view channel
Image: RaDaR ST uses a tumor-informed approach that identifies up to 48 patient-specific variants through whole-exome sequencing and tracks those variants in plasma to detect circulating tumor DNA (ctDNA) at very low variant allele fractions (VAFs) (Photo courtesy of Neogenomics)

Tumor-Informed MRD Assay Gains Medicare Coverage for Immunotherapy Monitoring

NeoGenomics’ RaDaR ST molecular residual disease (MRD) assay has received expanded coverage from the Centers for Medicare & Medicaid Services’ Molecular Diagnostic Services Program (MolDX) for monitoring... Read more